Category Archives: Dr.Cannabinergy Treasures

Assorted Essays and Papers From the Mind of Dr.Cannabinergy

BOSTON FREEDOM RALLY Prepared Speech, 9/15/12

(WATCH VIDEO OF ALL BUT LAST 2-3 mins of speech here:

Look at how far we’ve come on the elevation of cannabis respect and
human dignity.  It used to be that you would be looked at with stigma
and scorn if you wanted to invest time and energy into procuring
cannabis or growing some at home so you can consume it – no
exceptions.  Now, at least it pretty much makes common sense to folks
and legal sense in the eyes of 17 states and DC’s laws if you use
cannabis for particular doctor or prescriber-approved medical
purposes…such as if you have cancer, if you are undergoing cancer
treatment, if you have HIV/AIDS, if you have to take HIV antiviral
drugs, if you have multiple sclerosis, or other neurodegenerative
disorders, if you suffer from chronic persistent pain, or need strong,
more risky medicines to treat pain, if you have a seizure disorder, an
inflammatory bowel disorder like Crohn’s or Ulcerative Colitis, if you
have a wasting syndrome, poor appetite, glaucoma, and many other
conditions.  There has been a major shift in the state-by-state,
region-by-region attitude on this over the last 15 years.  There are
approximately 1,000,000 approved medical cannabis using patients under
the authorization of over 10,000 physicians and prescribers across the
United States.  People are being seriously helped!  Certainly, there
is much more that needs to be done to make cannabis treatments more
available for these types conditions which are often treated with more
severe side-effect producing medications. Many patients and doctors
are simply in the dark.
Unfortunately, instead of supporting education and the development of
these local medicine systems, federal government leaders and
bureaucrats have gone the way of facilitating a pharmaceutical
privileged-legitimacy monopoly on this 37 million year old
commonwealth medicinal plant.  They have given the go-ahead for a
pharmaceutical company to go through US testing of a highly
characterized hash oil made from a big grow-op in Great Britain. At
the same, the federal government has given nothing but grief and
permission-DENIED slips to well-meaning academics and non-profits,
even here in Massachusetts, who want to grow cannabis for similar
testing.  Yes, this is the American federal government giving
privileged access to venture-capital infused PHARMA companies and
ruining, throwing in jail, and pointing guns at the heads of people
who are doing a complementary and alternative medicine approach with
this ancient medicinal herb in places like CA, CO, MT, WA, and other
Since this is a freedom rally, let me take a moment to recognize here
and now how our UNIVERSAL SCIENTIFIC FREEDOM to explore and
investigate very exciting and promising medical applications for
cannabis is being explicitly restricted in this country.  Thanks to
the wonder of how compounds in cannabis known as cannabinoids interact
with our body’s evolutionary ancient endocannabinoid system,
applications for cannabis such as brain cancer killing and other types
of cancer killing, Lou Gerhig’s disease halting and Multiple Sclerosis
slowing or halting, Alzheimer’s disease preventing, stroke and brain
injury recovery boosting, osteoporosis fighting, PTSD alleviating,
MRSA bacteria-superbug destroying, mad cow disease fighting, HIV
suppressing – all have strongly been suggested over and over in high
quality pre-clinical and early clinical scientific research in
reputable labs here and around the world.  We are not free in this
country, this “land of the free”, to test these applications out in
big clinical and treatment trials in humans using our own local grows
of cannabis because of these irrational prohibitionist laws. It is not
that the testing is expensive, too dangerous, or beyond our
technological and scientific means.  It is just a straight up
ideological ban.  This is like, 400 years ago in Europe, yanking away
Galileo’s telescope just after he’s caught a glimpse of the moons of
Jupiter and imagined a new celestial map.  This is just what Catholic
Church leaders—the power-that-be back then—did, out of fear of losing
their control and power.  But the world did move on and astronomy
moved forward.  How many years will advancement in the field of
medicine and human health be delayed by the federal government’s
WHEN DO WE WANT IT?  NOW! (repeat)

There are plenty of reasons people might want to use cannabis – for
example to improve their quality of life, expand their horizons, or
facilitate social bonding.  We are getting to a point culturally and
scientifically where we recognize that the human desire to alter
consciousness with psychoactive substances other than alcohol,
caffeine, energy drinks, tobacco, chocolate, hot chilies, and sugar is
normal and should be treated in a non-criminalizing, non-stigmatizing
public health manner which maximizes benefits and minimizes harms.
For now, we have remember: repression breeds obsession!  We have to be
careful not fall for the knee-jerk reaction of obsession with the
forbidden fruit cannabis—because that itself is a diminishment of

Here are some things you can do to advance the cause of health and
scientific freedom:
QUESTIONS 2 and 3 this November.  QUESTION 2 will allow terminally ill
patients of sound mind with less than six months to live the right
exercise the option of physician-assisted death if they so choose to
minimize needless suffering.  QUESTION 3 will legalize the medicinal
use of cannabis for patients who have been authorized to use it under
a doctor’s care. In this state possession of small amounts of cannabis
has been decriminalized already so that will help keep the program
less susceptible to fraud.  Both of these measures will leap
Massachusetts ahead in the cause of improved health and respect for
human rights and patient autonomy.
2.      If are a licensed medicine prescriber—a physician, a
physician-assistant, or nurse practitioner—or if you know one, please
visit or have them visit, ASA, where I’m a
board member, and sign a sign-on letter saying that you agree that
there is an currently accepted medical use for cannabis in the United
States. This should help raise the profile of a case in federal court
next month in which the government’s archaic position will be
challenged once again.
3.      Visit my website at and my instructional videos at!  Support the Boston Freedom Rally!  They went through
great efforts to keep this space alive!

Education vs. Indoctrination

Dr.Cannabinergy, Sunil Kumar Aggarwal MD, PhD, speaking out about CannabisiEducation vs. Indoctrination

by Sunil Aggarwal on Friday, September 28, 2007 at 2:06pm

Education vs. Indoctrination

Education: [ej-oo-key-shuhn] – noun. The act or process of imparting or acquiring general knowledge, developing the powers of reasoning and judgment, and generally of preparing oneself or others intellectually for mature life.

Indoctrination: in.doc.tri.nate [in-dok-truh-neyt] – verb (used with object), – nat.ed, To instruct in a doctrine, principle, ideology, etc., esp. to imbue with a specific partisan or biased belief or point of view. [ Unabridged (v 1.1)]

Dr,Cannabinergy, Sunil Kumar Aggarwal MD, PhD, Physician-Scientist and Medical GeographerAsk Your Questions and Talk to Dr.Cannabinergy

Who’s Who in Medical Cannabis – Sunil K Aggarwal, MD, PhD – by c.a. riley

American Alliance for Medical Cannabis (AAMC)

Ten years ago the American Alliance for Medical Cannabis was formed by Dr. Jay R. Cavanaugh to promote the medical uses of marijuana. AAMC became a member of the Coalition for Rescheduling Cannabis which filed a petition with the federal government to remove marijuana from their “no medical use” classification. Nine years later the government has denied the petition.

AAMC now has directors active in 19 states (Arizona, California, Colorado, Georgia, Idaho, Kansas, Kentucky, Michigan, Nebraska, New Jersey, New Mexico, Ohio, Oklahoma, Oregon, Rhode Island, Utah, Washington, West Virginia, and Wisconsin). We are helping patients find the resources they need in order to benefit from medical cannabis.

[SlideDeck id='2795' width='100%' height='420px']

Dr.Cannabinergy, Sunil Kumar Aggarwal, MD, PhD, Physician-Scientist and Medical Geographer
Dr.Cannabinergy, Sunil Kumar Aggarwal, MD, PhD, Physician-Scientist and Medical Geographer

Who’s Who in Medical Cannabis -Sunil K Aggarwal, MD, PhD – by C.A.Riley


Dr Aggarwal is one of the most effective medical cannabis proponents few people outside the Seattle area have ever heard of.

It has been easy to find documentation of his myriad achievements in education, research, medicine, medical cannabis advocacy and more, but it has been nearly impossible to ferret out any personal information on Dr Aggarwal.

As a University of Washington medical student, Aggarwal told the crowd at the 2008 Seattle Hempfest, “We have to change the way people think about people and cannabis. This is a staple of the earth and a basic medicine for a lot of people.”

Long before his time at the University of Washington, in the early 1990s Sunil Aggarwal attended high school in Muskogee, Oklahoma until his Junior year when he went on to the Oklahoma School of Science and Mathematics in Oklahoma City.

After finishing high school, Aggarwal left the Midwest in 1997 and traveled to the west coast, where he resumed his education at UC Berkeley–which included a semester of study abroad in Edinburgh. After 4.5 years at Berkeley, Sunil moved to Seattle and continued his studies at the University of Washington in the Geography Department.

There, he completed his first two years of med school, completed his doctorate in geography, writing his dissertation on the “medical geography of cannabinoid botanicals in Washington State.” Two more years of med school followed, in which Aggarwal focused on the Medical Scientist Training Program and the Global Health Pathway, graduating in June, 2010, some two years after his Hempfest proclamation. Dr Aggarwal also holds degrees in chemistry, philosophy and religious studies.

In conjunction with his dissertation, Dr Aggarwal conducted research with 176 chronically and critically ill patients in two groups, one from a rural pain clinic and the other from an urban cannabinoid botanical delivery clinic. At this writing, two peer-reviewed published articles have come from this work.

So, what led Dr Aggarwal to the medical cannabis movement?

It began while he was an undergraduate.

He says that when he discovered “marijuana wasn’t a horribly dangerous thing” he wanted to study it thoroughly and he has done so for at least the past decade.

When medical student Sunil K. Aggarwal convinced the UW chapter of the medical student group of the AMA to support a resolution he had written in support of rescheduling cannabis, he presented the idea and his research to the American Medical Association (AMA) at its annual meeting in 2008. The organization agreed to study the issue for a year.

At its 2009 meeting, the country’s largest physicians’ organization formally adopted a policy urging the federal government to reclassify, or “reschedule,” cannabis.

It was Aggarwal’s research, dissertation, and the two articles derived from it and published in the Journal of Opioid Management that helped convince the American Medical Association (AMA) of the potential for medical uses of cannabis and led the organization to reverse previous policy and call for the rescheduling of cannabis so that more research could be conducted upon it.

So far, the government has not changed its policy and, incredibly, has stepped up efforts to quash medical cannabis production in the states that have legalized it for medical use.

Dr Aggarwal also holds degrees in chemistry, philosophy and religious studies and is a much-sought-after speaker at medical, drug policy reform and other conferences and conventions.

Here’s a link to an interesting article by Dr Aggarwal. Aggarwal-Macroed.pdf

His new website:

The report drafted by the AMA’s Council on Science and Public Health asks for a “review” of marijuana’s classification but neither demands the government reschedule the drug nor emphasizes the need Aggarwal believes hundreds of thousands of patients have for the drug’s medicinal properties.

“I tried as best as I could to make the language stronger than it was, but that was as far as it was going,” Aggarwal said. “But I realized that even at that level, it would still be a big shift.”

And not just for the medical community. Speaking at Hempfest last year, Aggarwal urged the crowd not to feel like criminals.

The government hasn’t shown any sign of following the AMA’s suggestion just yet, though it’s hardly the first organization to call for change. Last year, the American College of Physicians also urged the government to reconsider marijuana.

Aggarwal, who expects to stay in what he calls the now “exploding” field of cannabinoid science after he graduates in June, is sure change is coming.

“I’m pretty happy,” he said. “This Schedule 1 thing is going to be a thing of the past.”


Dr,Cannabinergy, Sunil Kumar Aggarwal MD, PhD, Physician-Scientist and Medical GeographerAsk Your Questions and Talk to Dr.Cannabinergy

Intoxication: The Fourth Human Drive and Pharmacologicalism

[SlideDeck id='2765' width='100%' height='420px']

Dr.Cannabinergy, Sunil Kumar Aggarwal, MD, PhD on Human Intoxication
Dr.Cannabinergy, Sunil Kumar Aggarwal, MD, PhD on Human Intoxication

Weapons of mass destruction (weapons-grade fissile nuclear material (reprocessed plutonium or yellowcake uranium), biological weapons (e.g. Ebola, Fusarium)), Chemical Toxins (lead (Pb), mercury (Hg), NOx emissions, fine particulate matter, PBTs such as PCBs and PBDEs, mixed radioactive nuclear waste), Greenhouse Gas emissions (CO2­­, CH­4, H2­O(g)­) —

These are the substances and chemicals that, for the sake of a healthy, peaceful, and sustainable world, we need policies implemented to heavily curtail, reduce and/or abolish their production and use.

What can obscure and retard these goals are public policies that attempt to control/eradicate substances that are treated as if they were nuclear fissile materials or virulent contagions. “Drugs” are one set of substances that get in the way of these goals due to the influence of powerful interest groups who persist in claiming that drugs require massive curtailment, reduction, and total eradication.

This rhetoric, while sounding totally normal and familiar due to its oft-repetition, is not based on science or reason. Drug-taking is a normal and ordinary aspect of human culture that has appeared universally cross-culturally and throughout recorded history and prehistory. Not everyone is satisfied with the national “un-drug” drug alcohol, and it is chauvinistic to force people to be so.

Allow me to quote from a manuscript by a Canadian drug policy analyst that is about the debunked mythology of the Marijuana Gateway:

We also need to learn to accept the reality that mental health is as important as physical health. The Vedas are believed to be among the oldest, if not the oldest, religious scriptures extant. One of them, the Rig Veda, specifically focuses on the worship of a psycho-active substance that opens the doors to intense spiritual experience. A number of other scriptures, from various religions, seem to cover the same ground, although usually in a more disguised form. Even the Bible has numerous entries that could plausibly be references to cannabis and powerful psychedelics.

The need to explore human consciousness is as vital as the need to eat or sleep. Since time immemorial and until the end of time, humans have been, and will be, using drugs or plants that seem to facilitate interesting or productive explorations and, without the opportunity to use them under supervised conditions, many people will inevitably be misusing them as long as their dominant cultures, to which they’re pressured to conform, continue to insist that these substances have no legitimate use.

Some psychopharmacologists have described this acquired human drive to psychoactivate as “the fourth drive.”

Thus, taking it into account is essential for a full understanding of human health.

The ‘war on drugs’ or ‘drug abuse prevention and control’ is therefore more appropriately seen as a low-grade, persistent, prisoner-taking war on the acquired human drive to psychoactivate steeped in an ideology of pharmacologicalism in which some substances are allowed and encouraged for psychoactivation (e.g, tobacco, alcohol, caffeine, sugar, cacao, “better than well” mood brighteners) and others are morally forbidden.

Pharmacologicalism is a matrix of centralized powers and discursive practices whose object is to reinforce an essentialism of drugs, of angel drug and demon drugs.

Take a peek into the racist, morally panicked and drug scare history.

Former Congressman, Spanish-American War hero, and prohibition propagandist Richmond P. Hobson issued the following national radio broadcast in 1928 during the “Narcotic Education Week”:

Heroin addiction can be likened to a contagion. Suppose it were announced that there were more than a million lepers among our people. Think what a shock the announcement would produce! Yet drug addiction is far more incurable than leprosy, far more tragic to its victims, and is spreading like a moral and physical scourge.

There are symptoms breaking out all over our country and now breaking out in many parts of Europe which show that individual nations and the whole world is menaced by this appalling foe…marching…to the capture and destruction of the whole world.

Most of the daylight robberies, daring holdups, cruel murders and similar crimes of violence are now known to be committed chiefly by drug addicts, who constitute the primary cause of our alarming crime wave.

Drug addiction is more communicable and less curable than leprosy. Drug addicts are the principle carriers of vice diseases, and with their lowered resistance are incubators and carriers of the streptococcus, pneumococcus, the germ of flu, of tuberculosis, and other diseases.

Upon the issue hangs the perpetuation of civilization, the destiny of the world and the future of the human race.

(quoted in The American Disease: Origins of Narcotic Control by Dr. David Musto, Yale Professor and UW Medical School graduate)

My main point is that psychoactivity is not the same as dangerous toxicity, despite the histrionic ranting of Mr. Hobson!

Despite this, the United States Drug Enforcement Administration/Agency maintains over 78 offices in 56 countries outside the US, reflecting the hegemonic status that the United States has enjoyed since the early 20th century in matters related to international drug control.

This is total insanity.

When are we going to separate the effects of drug prohibition from drug use?

Why do we not strengthen our call for the eradication of dangerous substances by pointing out the violence and irrationality of spending approximately 100 billion dollars a year on curtailing naturally occurring seeds which mature into plants that satisfy the natural human drive to psychoactivate?

Let’s advocate for the public-health backed policy of harm reduction and strengthen our credibility on speaking up for the truly dangerous substances.



Dr,Cannabinergy, Sunil Kumar Aggarwal MD, PhD, Physician-Scientist and Medical GeographerAsk Your Questions and Talk to Dr.Cannabinergy

Cannabis Policy Reforms at the American Medical Association

Dr.Cannabinergy, Sunil Kumar Aggawal Showing His Skills
Dr.Cannabinergy, Sunil Kumar Aggarwal Showing His Skills

Cannabis Policy Reforms:

by Sunil Aggarwal on Sunday, November 21, 2010 at 1:09am

Greetings, Fellow Internet Users,

People have been asking what the ol’ doctors’ trade guild association, the AMA, have resolved about Cannabis and its use as a medicinal agent.  Well, a few interesting things.  First, a brief review from last year.   The AMA filed a report written by their Council on Science and Public Health entitled “Use of Cannabis for Medicinal Purposes” on November 9, 2009, in which it was acknowledged that short-term clinical trials of smoked cannabis grown in Mississippi with federal tax dollars had demonstrated evidence of its ability to relieve neuropathic pain, stimulate appetite, and ease muscle spasms in humans.  They furthermore adopted a policy recommendation from the report saying that “Our AMA urges marijuana’s status as a Schedule I drug be reviewed…”  The report also said that rescheduling of marijuana could be supported if it aided in the development of cannabinoid medicines.   Since last November, the report was kept on a website open only to AMA members and was to be published in a peer-reviewed journal, but this never occurred.  Members of the press did get copies if requested, and human rights activist groups quickly shared it online, as did eventually the Board of Pharmacy of Oregon.  Worldwide headlines took “reviewed” to mean “reconsidered”, which it essentially does in this context.  It was also interpreted as saying the AMA calls on the Feds to stop classifying marijuana as dangerous.  The phrase “AMA marijuana” has generated hundreds of google news alerts since that time.  Earlier language that the Medical Student Section and several Pacific and Mountain state medical delegations had supported which called on “reclassification of marijuana’s status” to a more appropriate Schedule, did not make it.

Tthe AMA did disseminate its own news releases about their policy change.  The AMA president was interviewed about the policy change on National NPR and said that the issue was brought forward in the AMA by the pain and palliative care doctors (sadly, it was not in fact).  In the press since last year, AMA board members have made said stronger statements about cannabis.   For example, in Dec. 09, AMA board member Dr. Edward Langston told CNN, with regards to Cannabis, “We believe it is time for rescheduling, consideration of that…”  At another time, an AMA spokesperson told the press that more medical societies should adopt the AMA policy if change is to be seen in federal law (I cannot find the link to the article that said this).

This year, the Hawaii delegation, led by Dr. Webb, introduced a resolution to call for Cannabis to be scheduled no higher than THC (which certain formulations of are found in III).  In the process of considering this resolution (you can read it here:, a few things happened at the AMA meeting this year.  First, they summarized what action they had taken from the previous year’s resolution:

1. Status:

“A copy of the Council report and AMA policy statement requesting federal review of the current scheduling status of cannabis was forwarded to the Drug Enforcement Administration immediately after the 2009 Interim Meeting.”

2. Next, when the AMA Council on Science and Public Health was writing briefing notes about their positions on the various resolutions before them, with regards to the aforementioned resolution from Hawai’i, they wrote:

“The Council on Science and Public Health studied the issue of cannabis scheduling in a report issued at the 2009 Interim Meeting. This report also discussed the current processes and barriers to conducting clinical trials with a substance that is contained in Schedule I of the Controlled Substances Act. Nothing substantial has changed since that report was written in terms of the established science base for medicinal use of cannabis except that more states are considering adopting statutes or regulation to facilitate medicinal use outside of the traditional prescription and over-the-counter classifications of pharmaceuticals. Current policy urges that the federal government consider removing cannabis from Schedule I to facilitate the conduct of clinical research but does not endorse state-run programs.”

3. Ultimately, this resolution did not pass.  But the AMA House of Delegates took the opportunity to spruce up their current policy on this topic (pg 9 here:  For example, the title of their policy is no longer “Medical Marijuana” but “Cannabis for Medicinal Use” — nearly all instances where “marijuana” is mentioned in the policy have changed to “cannabis”.  Finally, some new language saying that “a special schedule should be developed for Cannabis” was introduced at the last minute by American Society of Addiction Medicine representatives who have been hostile to the policy change at the AMA since the beginning.  It probably means nothing, since no special schedules can be developed, except to make it seem like the AMA is not asking for Cannabis to move to a lower schedule, but a different and new one just for itself.  It really is nonsensical, and will probably amount to nothing.  However, the federal government might be able to have an easier time saying that it is acting in accordance with the wishes of the AMA when they keep Cannabis in Schedule I (which is clearly not true), which it seems they have every intention of doing for now.  After this meeting, again, the AMA sent out a meeting recap to all its members.  It said in the email: “The House weighed in on public health issues by extending support for universal influenza vaccination of health care workers to include seasonal and H1N1 influenza. It also urged that marijuana’s status as a federal Schedule I controlled substance be reviewed to facilitate clinical research and development of cannabinoid-based medicines.” (bold in original here).

Finally, the AMEDnews, the AMA’s official newspaper, wrote:

“Delegates also voted to ask the federal government to re-evaluate the Schedule 1 status of marijuana and related cannabinoids used for medical care to facilitate research. Much meaningful research is blocked by the current status, because researchers have to get special certification for studies involving Schedule 1 drugs, said Timothy McAvoy, MD, an internist from Waukesha, Wis., and a delegate for the Wisconsin Medical Society.”

So, in a nutshell,this month, we got a second AMA house of delegates to vote on marijuana liberalization and got the AMA to say a second time that marijuana’s schedule I status is suspect.  I think the fact that it was on the agenda at the meeting again this year, that the meeting was held in San Diego a few days after the election, and that the policy was essentially re-endorsed in possibly more friendly language is why there was a flurry of interest in the AMA stories from last year on this issue.

Thank you for your interest and support,

Sunil Aggarwal, MD, PhD

AMA member in good standing

By the way, here is an interesting article to read again in light of what the DEA head nominee said at her recent Senate hearing:


Dr,Cannabinergy, Sunil Kumar Aggarwal MD, PhD, Physician-Scientist and Medical GeographerAsk Your Questions and Talk to Dr.Cannabinergy

1966–When “Another War on Heresy” Was Declared

When Drug Control Was Handed to the Cops — 1966

by Sunil Aggarwal on Sunday, 07 November 2010 at 01:09

Man of Vision Testifying during a recent Senate subcommittee on juvenile delinquency, Timothy Leary tells the group that the LSD fad among the young is a “crisis of challenge” and not a “crisis of peril.” He was one of the chief witnesses called to the Washington hearings.


“The inevitable backlash from this new message of individual power began in 1966 when various legislatures and Congress began considering bills to criminalize L.S.D. and similar drugs. In this year I testified before two Senate committees urging that control of all mind-changing drugs be assigned to the medical profession supervised by Federal and State health agencies. I predicted that if control of drugs were administered by law enforcement agencies, the result would be a black market more irrational and widespread than that of alcohol prohibition and the growth of the enormous police-state repressive bureaucracy.

And who, indeed, wanted that?

My political position then was by no means radical or solitary. Indeed, during the Johnson administration, a bitter battle was fought on this issue. Medical and scientific people (backed by the Kennedys) urged that drugs be administered by the Department of Health, Education and Welfare, while law-and-order people politicked for the Department of Justice. History may well decide that the second belligerent disaster of the Johnson administration was the decision to turn drug control over to the police. L.S.D. was made illegal and most of the top drug scientists began their steady exit from government responsibility. Another war on heresy had been declared.”

–Timothy Leary, PhD, “Seeds of the Sixties” in Neuropolitics, 1977, but originally written in 1973 from Folsom State Prison. (page 18 in this  pdf, and pg 4-5 in book))

Dr,Cannabinergy, Sunil Kumar Aggarwal MD, PhD, Physician-Scientist and Medical GeographerAsk Your Questions and Talk to Dr.Cannabinergy

Inverting the Hierarchical Monopoly on Cannabis for the Good of the Commons

Dr.Cannabinergy, Sunil Kumar Aggarwal Breaking Down the Facts
Dr.Cannabinergy, Sunil Kumar Aggarwal Breaking Down the Facts

Breaking the Marij/huana Fear-Trance and Inverting the Hierarchical Monopoly on Cannabis for the Good of the Commons

by Sunil Aggarwal on Saturday, December 25, 2010 at 11:35pm

Will Transform:


1. The Alarm of Hearing: “Put Your Hands Up and Step Away From Your ____! (Cannabiniod Herbal Garden, Plant Farm, Hempen Flower, or Hempen Flower-Containing Mixture) ”


2. The Threat of Hearing “Put Your Positive ____ In This Cup!  (Phytocannabinoid Metabolite-Containing Personal Body Fluid or Hair Sample Being Used as Character- or Performance-Diminishing Evidence Against You)


3. The Blatant Deprivation of:  “You and Your Community Can’t Have This Illegal Plant.” (Resource Bioimporverization)


To the Value of Experiencing a Cannabis-Revitalized Commons Wealth With:


1. Global Planting of Cannabis Freely, Zoned Wisely, Utilized and Consumed Locally


2. Shared Development of the Provision of a Valuable Medicinal Plant, Relaxant, and Green Economic Material


3. Proliferation of Herbal Cannabinergic Yoga Studios and Safe Community Spaces: Healthy and Peaceful Spaces for Personal, Collective, and  Freely Chosen Cannabinergic Mind-Body Activation


Because to ‘go green’ means to evaluate our judgment of all Earthly wonders and all manners and species of life…


More Marij/huana Fear-Trance Breaking and Cannabis Commons-Revitalization To Be Continued…

Dr,Cannabinergy, Sunil Kumar Aggarwal MD, PhD, Physician-Scientist and Medical GeographerAsk Your Questions and Talk to Dr.Cannabinergy

Clearing Up Cannabis Confusion

Dr. Sunil Kumar Aggarwal MD, PhD
Dr. Sunil Kumar Aggarwal MD, PhD

Clearing Up Cannabis Confusion

Written by Dr. Sunil Aggarwal on December 26, 2010

Hemp, Reefer, Mari(h/j)una, Pot, Maryjane, Ganja, Chronic, Weed are all common names for one plant, Cannabis, which evolved 36 million years ago.

This can indeed be confusing, so let’s start from the beginning.

Humans and this plant, like all plants and animals on Earth, share a now-extinct, common ancestor which lived 1000-2000 million years ago. Cannabis, however, is one of our plant relatives which deserves special recognition. Cannabis has unique properties that make it valuable to humanity. Hence it was given the second name sativa, meaning ‘useful’ by Swedish botanist, physician, zoologist, and father of modern taxonomy Carolus Linnaeus in 1753. Going further back, texts from the 12th-10th century BCE (BEFORE the COMMON ERA) from the Vedic Civilization of the Indus Valley suggest an early, reverential view of Cannabis as a holy plant, which was provided on Earth for humanity to find relief from distress or woe (Atharva Veda, Book XI, Hymn 6, Verse 15). Similar sentiments are expressed in the writings of other ancient civilizations.

Uses of “Cannabis sativa” include production of textiles, building material, paper, and biofuel using the cellulose and fiber in its stalk, production of nutritive food, edible oil, and lotions using its oil-rich seeds and leaves, and, most mysteriously, production of herbal medicines, spiritual sacraments, and in-ebriants using its resin-producing flowers (just as sap is a resin made by trees).

It is this latter use of Cannabis that has generated all the commotion, and for which commotion, confusion, and controversy have seemingly been deliberately sown.

We now know that compounds termed cannabinoids, found in the resin from the flowers of the Cannabis plant, interact with a biological signaling system called the Endocannabinoid System. This system is vital in humans as it modulates many essential functions such as mood, movement, memory, pain, appetite, immunity, inflammation, nerve and neuron protection, reproductive function, and even tumor cell regulation, among many others

Anything that stimulates this system is described as “Cannabinergic”.

  • Therefore, hemp flowers are Cannabinergic.

If you had any confusion about Cannabis and Cannabinergy, it was intended to be so.

There has been much concerted effort in service of a distinct, but often hidden, sociopolitical agenda since the first third of the 20th century, to confuse and distort the knowledge base of schoolchildren and adults alike the world over regarding this widely found, semi-domesticated plant Cannabis sativa, especially in light of the groundbreaking scientific discoveries of cannabinoid signaling in human bodies and other living systems.

It is imperative for us to work together to learn more facts and unlearn the fallacies regarding this unique plant and its role in humanity.

Dr,Cannabinergy Cannabulating with other Cannabis Wizards
Dr,Cannabinergy Cannabulating with other Cannabis Wizards, Dr. Michelle Sexton, Sam Wayne Smith and Richard Brender


Dr,Cannabinergy, Sunil Kumar Aggarwal MD, PhD, Physician-Scientist and Medical GeographerAsk Your Questions and Talk to Dr.Cannabinergy

Cannabis World View

Dr. Sunil Kumar Aggarwal MD, PhD
Dr. Sunil Kumar Aggarwal MD, PhD

World View on Cannabis

If you see the word marijuana and you do not equate it with cannabis, then you have been misinformed about the plant kingdom, as cannabis has been negatively portrayed by using that talked-down name.

If you see the phrase medical marijuana, and you do not immediately think about the use of an ancient medicine in a scientifically informed and humane medical context, still inaccessible for many, then you have been kept in the dark about some very important facts.

Please consider five facts:

Fact 1: Cannabis is a 37 million-year-old botanical that contains a rich supply of cannabinoids.

Fact 2: Cannabis has been used as a medicine by humans in many parts of the world ever since the times of even the very earliest kept medical records.

Fact 3: Only about 20 years ago did scientists discover the reason behind cannabis’s reproducible actions–that humans bodies, and in fact much of life for the last 600 million years, have relied on their own internally made cannabinoids, or endocannabinoids, to maintain health and proper functioning, such as that related to appetite, mood, pain sensation, muscle activity, nerve protection, and many other areas.

Fact 4: When consumed, the phytocannabinoids, or plant cannabinoids, made by cannabis interact with the body’s endocannabinoid system, and thus can be used to restore function, relieve real medical symptoms, and treat maladies.

Fact 5: The field of cannabinoid medicine is blossoming. There are over 15,000 scientific studies published on cannabis and cannabinoids, over 2,000 on endocannabinoids, and 110 controlled clinical trials of cannabis and other cannabinoid-based medicines have been conducted in the last 30 years, involving over 6,100 patients.

With these facts in mind, one can potentially adjust their world view regarding cannabis.


Dr.Cannabinergy Groovin With The Wise One,  Dr.Tod Mikuriya, the Original Dr."C"
Dr.Cannabinergy Groovin With The Wise One, Dr.Tod Mikuriya, the Original Dr."C"

Cannabis Tipping Point

Dr.Cannabinergy, Sunil Kumar Aggarwal, MD, PhD
Dr.Cannabinergy, Sunil Kumar Aggarwal, MD, PhD

American Medical Association Position:

Regarding Cannabis

The largest physician-based group in the country, the American Medical Association (AMA), had for many years taken a stance that cannabis had no medicinal value.

All that changed on November 9, 2009 when the AMA voted to reverse its position by formally adopting a report drafted by the AMA’s Council on Science and Public Health, titled “Use of Cannabis for Medicinal Purposes” which affirmed the plant’s therapeutic benefits and called for further research.

The report concluded that “short-term controlled trials indicate that smoked cannabis reduces neuropathic pain, improves appetite and caloric intake especially in patients with reduced muscle mass, and may relieve spasticity and pain in patients with multiple sclerosis. The report recommended that “the Schedule I status of marijuana be reviewed with the goal of facilitating clinical research and development of cannabinoid-based medicines, and alternate delivery methods.”

Dr. Sunil Aggarwal, M.D., Ph.D., is one of the report’s designated expert reviewers.

Back in 2008, he spearheaded, with his colleagues from the Medical Student Section of the AMA, a resolution in support of reclassifying cannabis out of Schedule I. This resolution was an instrumental catalyst that lead to the November 2009 vote.

Upon this dramatic reversal by the AMA, Dr.Aggarwal remarked,“The AMA has written an extensive, well documented, evidence-based report that they are seeking to publish in a peer-reviewed journal that will help to educate the medical community about the scientific basis of botanical cannabis-based medicines. It’s been 72 years since the AMA has officially recognized that marijuana has both already-demonstrated and future-promising medical utility”

The following is an excerpt from the original 2008 Resolution:

Dr. Cannabinergy Brings About AMA Resolution
Dr. Cannabinergy Enjoying AMA Resolution


Resolution 2 (A-08)

Introduced by: Sunil Aggarwal, Aaron Flanagan, and Alicia Carrasco, University of Washington School of Medicine;
Sonya Khan and Liisa Bergmann, University of California, Los Angeles, School of Medicine;
Trace Fender, Northeastern Ohio Universities College of Medicine;
Leo Arko, University of New Mexico School of Medicine

Subject: Marijuana: Medical Use and Research

Referred to: MSS Reference Committee
(Despina Siolas, Chair)

1 Whereas, The federal Controlled Substances Act of 1970 categorized marijuana as a Schedule I substance
2 not permitted for prescription use1 , yet 12 states (AK, CA, CO, HI, ME, MT, NV, NM, OR, RI, VT
3 WA)2 have laws that permit the use of marijuana when recommended by a physician; and
5 Whereas, A ruling by the Ninth U.S. Circuit Court of Appeals reaffirmed and the Supreme Court let stand
6 the right of physicians and patients to discuss the therapeutic potential of marijuana, but patients who
7 follow their physicians advice are put at risk for up to one year in federal prison for possession of
8 marijuana, and up to five years in federal prison for growing one marijuana plant, as federal law does not
9 make a distinction between medicinal and other marijuana use3 ; and
11 Whereas, Legal access to marijuana for specific medical purposes has been supported by numerous
12 national and state medical organizations, including the National Academy of Sciences’ Institute of
13 Medicine, American College of Physicians, American Psychiatric Association’s Assembly, American
14 Academy of Addiction Psychiatry, American Academy of Family Physicians, California Medical
15 Association, Medical Society of the State of New York, Rhode Island Medical Society, American
16 Academy of HIV Medicine, HIV Medicine Association, Canadian Medical Association, British Medical
17 Association, and the Leukemia & Lymphoma Society4; and
19 Whereas, The Institute of Medicine concluded after reviewing relevant scientific literature -including
20 dozens of works documenting marijuana’s therapeutic value – that “nausea, appetite loss, pain, and
21 anxiety are all afflictions of wasting, and all can be mitigated by marijuana”5 ; and
23 Whereas, Subsequent studies since the 1999 Institute of Medicine report, including randomized, double
24 blind, placebo-controlled ones, continue to show the therapeutic value of marijuana in treating a wide
25 array of debilitating medical conditions, including relieving medication side effects and thus improving
26 the likelihood that patients will adhere to life-prolonging treatments for HIV/AIDS and Hepatitis C and
27 alleviating HIV/AIDS neuropathy, a painful condition for which there are no FDA-approved treatments6;
28 and
30 Whereas, Given marijuanas proven efficacy at treating certain symptoms and its relatively low toxicity
31 reclassification would reduce barriers to research and increase availability of cannabinoid drugs to
32 patients who have failed to respond to other treatments7 ; and

33 Whereas, “Only two cannabinoid drugs are currently licensed for sale in the U.S. (dronabinol [Marinol]
34 and nabilone [Cesamet]), and both are only available in oral form” and while “useful for some, these
35 drugs have serious limitations”8; and
37 Whereas, Reclassifying marijuana as medically useful should draw from medical experience with opiates,
38 which indicates that “opiates are highly addictive yet medically effective substances and are classified as
39 Schedule II substances,” but “there is no evidence to suggest that medical use of opiates has increased
40 perception that their illicit use is safe or acceptable”9; and

42 Whereas, “Preclinical, clinical, and anecdotal reports suggest numerous potential medical uses for
43 marijuana … unfortunately, research expansion has been hindered by a complicated federal approval
44 process, limited availability of research-grade marijuana, and the debate over legalization”10; and
46 Whereas, the National Institute on Drug Abuse (NIDA) generally supplies marijuana for the research of
47 harms and does not automatically provide marijuana to researchers who hold an FDA Investigational New
48 Drug (IND) and a Drug Enforcement Administration (DEA) Schedule I researcher’s registration for
49 marijuana11; and
51 Whereas, The federal government has obstructed privately funded research through NIDA’s monopoly
52 over the production of marijuana for research, as well as through the DEA’s refusal to license any
53 privately funded marijuana production facilities, even though DEA-licensed, private facilities produce
54 LSD, MDMA, psilocybin, mescaline, and other Schedule I drugs; and
56 Whereas, Despite these obstructions, the accumulated scientific data regarding marijuana’s safety and
57 efficacy in certain clinical conditions and its increasingly accepted medical use in treatment can no longer
58 be ignored12; therefore be it
60 RESOLVED, That our AMA support review of marijuana’s status as a Schedule I controlled substance,
61 its reclassification into a more appropriate schedule, and revision of the current protocol for obtaining
62 research-grade marijuana so that it conforms to the same standards established for obtaining every other
63 scheduled drug for legitimate research purposes; and be it further
65 RESOLVED, That our AMA strongly support exemption from federal criminal prosecution, civil
66 liability, and professional sanctioning for physicians who recommend medical marijuana in accordance
67 with state law, as well as full legal protections for patients who use medical marijuana under these
68 circumstances; and be it further
70 RESOLVED, That this resolution be promptly forwarded to the House of Delegates at A-08 for national
71 action.

Fiscal note: TBD
Date received: 4/10/08
1. Drug Enforcement Administration (DEA) drug scheduling. Available at
2. USA Today. “Medical marijuana laws vary among states.” (2007) Available at
3. DEA federal penalties for marijuana. Available at
4. Endorsements document. Available at
5. Joy, J., Watson, S., and Benson, J. Marijuana and Medicine: Assessing the Science Base. National Academy Press,1999 6.deJong B.C., et al,”Marijuana Use and its Association With Adherence to Antiretroviral Therapy Among HIVInfected
Persons With Moderate to Severe Nausea,” Journal of Acquired Immune Deficiency Syndromes,
January 1, 2005; Sylvestre D.L., Clements B.J., and Malibu Y., “Cannabis Use Improves Retention and
Virological Outcomes in Patients Treated for Hepatitis C,” European Journal of Gastroenterology and
Hepatology, September 2006; Abrams D., et al, “Cannabis in Painful HIV-Associated Sensory Neuropathy,”
Neurology, February 13, 2007.
7. American College of Physicians, “Supporting Research into the Therapeutic Role of Marijuana,” January 2008:
10. Available at
8. Ibid, p 8.
9. Ibid, p 10.
10. Ibid, p 3.
11. National Institutes of Health. (1999) Announcement of the Department of Health and Human Services’
Guidance on Procedures for the Provision of Marijuana for Medical Research. Available at
12. E Lawrence O. Gostin, JD, LLD (Hon), Georgetown Law Professor, “Medical Marijuana, American Federalism, and the Supreme Court.” JAMA. 2005;294:842-844.

Relevant AMA and MSS Policy:

H-95.952 Medical Marijuana
(1) Our AMA calls for further adequate and well-controlled studies of marijuana and related cannabinoids in patients who have serious conditions for which preclinical, anecdotal, or controlled evidence suggests possible efficacy and the application of such results to the understanding and treatment of disease. (2) Our AMA recommends that marijuana be retained in Schedule I of the Controlled Substances Act pending the outcome of such studies. (3) Our AMA urges the National Institutes of Health (NIH) to implement administrative procedures to facilitate grant applications and the conduct of well-designed clinical research into the medical utility of marijuana.
This effort should include: a) disseminating specific information for researchers on the development of safeguards for marijuana clinical research protocols and the development of a model informed consent on marijuana forinstitutional review board evaluation; b) sufficient funding to support such clinical research and access for qualified investigators to adequate supplies of marijuana for clinical research purposes; c) confirming that marijuana of various and consistent strengths and/or placebo will be supplied by the National Institute on Drug Abuse to investigators registered with the Drug Enforcement Agency who are conducting bona fide clinical research studies that receive Food and Drug Administration approval, regardless of whether or not the NIH is the primary source of grant support. (4) Our AMA believes that the NIH should use its resources and influence to support the development of a smoke-free inhaled delivery system for marijuana or delta-9-tetrahydrocannabinol (THC) to reduce the health hazards associated with the combustion and inhalation of marijuana. (5) Our AMA believes that effective patient care requires the free and unfettered exchange of information on treatment alternatives and that discussion of these alternatives between physicians and patients should not subject either party to criminal sanctions. (CSA Rep. 10, I-97; Modified: CSA Rep. 6, A-01)
100.006 MSS Reclassification of Heroin for Therapeutic Use
AMA-MSS will ask the AMA to: (1) strongly support research into the therapeutic use of heroin as a Schedule I drug in the context of addiction treatment, for those patients for whom other standard methods have been tried and have failed; and (2) urge the Drug Enforcement Administration, Department of Health and Human Services, and National Institute of Drug Abuse to allow such research with appropriate oversight and safeguards. (MSS Sub Res 20, A-98) (AMA Res 504, I-98, Not Adopted) (Reaffirmed: MSS Rep E, I-03)
H-95.995 Health Aspects of Marijuana
Our AMA: 1. discourages marijuana use, especially by persons vulnerable to the drug’s effects and in high-risk situations; 2. supports the determination of the consequences of long-term marijuana use through concentrated research; and 3. supports the modification of state law to reduce the severity of penalties for possession of
marijuana. (CSA Rep. D, I-77; Reaffirmed: CLRPD Rep. C, A-89; Reaffirmed: Sunset Report, A-00)

H-95.997 Marijuana
Our AMA:
1. recommends personal possession of insignificant amounts of that substance be considered a misdemeanor with commensurate penalties applied; 2. believes a plea of marijuana intoxication not be a defense in any criminal proceedings; and 3. urges that educational efforts be expanded to all segments of the population.
(BOT Rep. J, A-72; Reaffirmed: CLRPD Rep. C, A-89; Reaffirmed: Sunset Report, A-00)

Dr.Cannabinergy, Sunil Kumar Aggarwal, on the American Drug War Panel
Dr.Cannabinergy, Sunil Kumar Aggarwal, on the American Drug War Panel